Does An Upgrade In Relative Strength Make This Biotech A Buy?

“When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength,” advises the author of today’s article, who further notes that “Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves.” With the biotech stock featured having seen its RS rating move from 80 to 83 recently, is it a buy? CLICK HERE.